THE 60-SECOND GUIDE
CJC-1295
Limited controlled human pharmacology.
Guide prepared November 13, 2026 · profile review dates retained
What is it?
CJC-1295 is an experimental long-acting growth-hormone-releasing hormone analog. Small human studies measured increases in growth hormone and IGF-1, rather than establishing benefits for recovery, athletic performance, or healthy aging. [1]
Potential benefits
Small controlled studies demonstrated prolonged stimulation of growth hormone and IGF-1. Those pharmacodynamic findings do not establish meaningful clinical benefit for wellness or athletic goals. [1]
Evidence & its limits
A measurable hormone increase is not a demonstrated improvement in health or function. FDA describes limited clinical data and concerns involving immunogenicity and impurities, and identifies serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilation. [1]
Risks & unknowns
FDA identifies limited clinical data, potential immunogenicity and peptide-impurity concerns. FDA has identified serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction. Long-term safety and clinical outcomes remain uncertain. [1]
Status & scope
Not FDA-approved. Small controlled hormone-response studies do not establish recovery, athletic performance or healthy-aging benefits. [1]
The question to ask
Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.
CHECK THE RECORD
Sources & review
- Full evidence record, references and review dates
- FDA compounding safety assessment
- CJC-1295 controlled human pharmacology, 2006
- Human pharmacology study · JCEM
Guide prepared November 13, 2026 · profile review dates retained. Condensed from the linked site evidence record. This format update is not a new clinical review of every source. Consult the full profile for its evidence-review dates and targeted updates.
Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.